A superior, next generation
transgenic platform

Tailored licensing options

Ablexis Announces Expansion
of Non-Exclusive Perpetual License Agreement with Eli Lilly and Company

About

The industry's leading transgenic platform.

MORE
Technology

For efficient discovery and development of antibody and antibody-derivative drug candidates.

MORE
Licensing

Our license options are designed to meet the needs of our partners.

MORE
News & Events

Ablexis Announces Expansion of Non-Exclusive Perpetual License Agreement with Eli Lilly and Company

MORE